Your browser doesn't support javascript.
loading
Opioid use disorder treatment and the role of New Jersey Medicaid policy changes: perspectives of office-based buprenorphine providers.
Mahone, Anais; Enich, Michael; Treitler, Peter; Lloyd, James; Crystal, Stephen.
Afiliação
  • Mahone A; Center for Health Services Research, Institute for Health, Health Care Policy and Aging Research, Rutgers, The State University of New Jersey, New Brunswick, NJ, USA.
  • Enich M; School of Social Work, Rutgers, The State University of New Jersey, New Brunswick, NJ, USA.
  • Treitler P; Center for Health Services Research, Institute for Health, Health Care Policy and Aging Research, Rutgers, The State University of New Jersey, New Brunswick, NJ, USA.
  • Lloyd J; School of Social Work, Rutgers, The State University of New Jersey, New Brunswick, NJ, USA.
  • Crystal S; Center for Health Services Research, Institute for Health, Health Care Policy and Aging Research, Rutgers, The State University of New Jersey, New Brunswick, NJ, USA.
Am J Drug Alcohol Abuse ; 49(5): 606-617, 2023 09 03.
Article em En | MEDLINE | ID: mdl-37506336
ABSTRACT

Background:

In the US, seventy percent of drug-related deaths are attributed to opioids. In response to the ongoing opioid crisis, New Jersey's (NJ) Medicaid program implemented the MATrx model to increase treatment access for Medicaid participants with opioid use disorder (OUD). The model's goals include increasing the number of office-based treatment providers, enhancing Medicaid reimbursement for certain treatment services, and elimination of prior authorizations for OUD medications.

Objectives:

To explore office-based addiction treatment providers' experiences delivering care in the context of statewide policy changes and their perspectives on treatment access changes and remaining barriers.

Methods:

This qualitative study used purposive sampling to recruit office-based New Jersey medications for opioid use disorder (MOUD) providers . Twenty-two providers (11 females, 11 males) discussed treatment experiences since the policy changes in 2019, including evaluations of the current state of OUD care in New Jersey and perceived outcomes of the MATrx model policy changes.

Results:

Providers reported the MOUD climate in NJ improved as Medicaid implemented policies intended to reduce barriers to care and increase treatment access. Elimination of prior authorizations was noted as important, as it reduced provider burden and allowed greater focus on care delivery. However, barriers remained, including stigma, pharmacy supply issues, and difficulty obtaining injectable or non-generic medication formulations.

Conclusion:

NJ policies may have improved access to care for Medicaid beneficiaries by reducing barriers to care and supporting providers in prescribing MOUD. Yet, stigma and lack of psychosocial supports still need to be addressed to further improve access and care quality.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Buprenorfina / Transtornos Relacionados ao Uso de Opioides Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Buprenorfina / Transtornos Relacionados ao Uso de Opioides Idioma: En Ano de publicação: 2023 Tipo de documento: Article